Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
$7.10
-4.3%
$7.89
$2.28
$9.01
$1.06B1.731.48 million shs923,036 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$0.43
-9.0%
$1.03
$0.42
$4.70
$19.04M1.47184,845 shs181,671 shs
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$1.04
-3.3%
$1.27
$0.99
$3.04
$392.25M1.622.35 million shs935,724 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.19
-0.4%
$1.43
$1.08
$3.70
$352.96M1.8610.13 million shs7.94 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
-6.68%-9.85%-8.74%+2.92%+176.49%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-19.52%-21.11%-39.63%-77.88%-88.73%
Standard BioTools Inc. stock logo
LAB
Standard BioTools
-9.32%-6.14%+0.94%-41.21%-59.77%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-6.30%-4.03%-11.85%-40.20%-64.58%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
4.0095 of 5 stars
3.51.00.04.23.42.50.6
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3.7693 of 5 stars
3.53.00.04.50.71.70.6
Standard BioTools Inc. stock logo
LAB
Standard BioTools
1.9658 of 5 stars
3.32.00.00.00.04.20.6
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.5242 of 5 stars
3.33.00.00.03.10.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
3.00
Buy$9.4032.49% Upside
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3.00
Buy$4.50944.08% Upside
Standard BioTools Inc. stock logo
LAB
Standard BioTools
2.50
Moderate Buy$2.50141.55% Upside
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.54
Moderate Buy$2.46107.45% Upside

Current Analyst Ratings Breakdown

Latest LAB, ADPT, PACB, and HBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/25/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$6.00 ➝ $2.00
3/24/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSpeculative Buy ➝ Speculative Buy$5.50 ➝ $4.50
3/21/2025
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$8.00 ➝ $9.00
2/27/2025
Standard BioTools Inc. stock logo
LAB
Standard BioTools
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Sector Weight
2/20/2025
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $11.00
2/20/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.50 ➝ $2.00
2/18/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$1.75 ➝ $1.50
2/14/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$2.50 ➝ $2.50
2/13/2025
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$10.00 ➝ $12.00
1/28/2025
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$5.50 ➝ $7.50
1/23/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$2.25 ➝ $1.75
(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
$178.96M5.89N/AN/A$1.37 per share5.18
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$94.14M0.20$0.08 per share5.16$1.71 per share0.25
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$174.43M2.25N/AN/A($1.85) per share-0.56
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$154.01M2.29N/AN/A$2.62 per share0.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
-$159.49M-$1.09N/AN/AN/A-89.12%-64.65%-26.45%5/6/2025 (Estimated)
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$3.41M-$0.29N/AN/A-14.57%-4.64%-2.40%5/5/2025 (Estimated)
Standard BioTools Inc. stock logo
LAB
Standard BioTools
-$74.66M-$0.55N/AN/AN/A-79.92%-27.05%-15.52%5/6/2025 (Estimated)
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$308.65M-$1.64N/AN/AN/A-200.40%-42.89%-14.77%5/8/2025 (Estimated)

Latest LAB, ADPT, PACB, and HBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/13/2025Q4 2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.20-$0.20N/A-$0.49$39.20 million$39.22 million
2/11/2025Q4 2024
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
-$0.27-$0.23+$0.04-$0.23$46.05 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
Standard BioTools Inc. stock logo
LAB
Standard BioTools
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
N/A
2.89
2.81
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.52
2.06
0.91
Standard BioTools Inc. stock logo
LAB
Standard BioTools
N/A
3.76
3.41
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.97
9.74
8.64
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Co. stock logo
ADPT
Adaptive Biotechnologies
790148.58 million138.43 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
49044.07 million39.69 millionOptionable
Standard BioTools Inc. stock logo
LAB
Standard BioTools
620378.99 million174.59 millionOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730297.85 million267.29 millionOptionable

Recent News About These Companies

Cathie Wood’s ARK Investment bought 899K shares of PacBio today
Jim Gibson to join PacBio as Chief Financial Officer
Cathie Wood’s ARK Investment bought 415K shares of PacBio today

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$7.10 -0.32 (-4.25%)
As of 12:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$0.43 -0.04 (-8.96%)
As of 12:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Standard BioTools stock logo

Standard BioTools NASDAQ:LAB

$1.03 -0.04 (-3.27%)
As of 12:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.18 -0.01 (-0.42%)
As of 12:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.